

Monday, 5 December 2005

100 FOLD INCREASE IN TRANSDERMAL DELIVERY OF NALTREXONE

OBJ Limited (OBJ) announced today that results from independent University studies had shown that the company's transdermal drug delivery technology had successfully delivered Naltrexone through-the-skin.

Naltrexone is an opioid antagonist used in the treatment of alcohol and heroin addiction.


The study, conducted by the Western Australian Biomedical Research Institute (WABRI) used donated human epidermis in an in-vitro transdermal diffusion study which compared Dermaportation enhanced delivery against passive or unassisted delivery. The results showed that Dermaportation could increase transdermal delivery of Naltrexone by up to 100 times.

Naltrexone is a problematic drug in terms of administration. It is unsuited to oral administration, due to poor bio-availability and adverse gastro-intestinal side-effects which result in poor patient compliance. To overcome these difficulties Naltrexone is usually administered via depot injections. The cost of this approach is high, labour-intensive and requires surgical conditions to administer. In addition, such system can suffer from inconsistent delivery and release rates as well as local reactions. Administering Naltrexone through the skin would avoid these problems, however previous attempts have had limited success due to the size of the molecule, its incompatibility with the skin and the need to achieve specific plasma concentrations.

The 100 fold increase in delivery rates achieved by the OBJ drug Patch technology has the potential to overcome these difficulties.

As with a number of other

drugs and vaccines recently trialed, OBJ could be the first to market with a through-the-skin Naltrexone delivery solution.



OBJ Limited (ACN 056 482 636)

Ground Floor, 284 Oxford Street, Leederville, Western Australia 6007

Phone: +61 8 9443 3011 Fax: +61 8 9443 3866 Email: jedwards@obi.com.au

OBJ
LIMITED

RESEARCH AND DEVELOPMENT

Background to the Announcement


OBJ Limited is a drug delivery company, specializing in electronic “drug patch” technologies that allow drugs, vaccines, therapeutic agents and cosmetic compounds to be delivered more effectively and more efficiently through-the-skin.

The OBJ Dermaportation system has been shown to manage and control the transdermal delivery of a broad range of drugs and therapeutic agents ranging from small difficult molecules such as Caffeine, through to large macro-globular proteins drugs such as vaccines.

OBJ's technology has been independently proven in both in-vitro and in-vivo studies and can manage a broader range of molecular sizes, structures and valencies than other active or passive drug delivery systems.

OBJ has been successful in managing the through-the-skin delivery of drugs used in the inflammation, pain, cancer and cosmetic fields.

OBJ's technology is low cost, and can be incorporated into reusable drug patches, (as illustrated) disposable single use drug patches and in a range of packaging systems for OTC and retail use.



Sustainable Benefits

Low cost and controlled through-the-skin delivery of drugs, hormones, vitamins, vaccines, anti-bodies and anti-aging molecules has long been the desire of the pharmaceutical industry. It would provide economic, safety and efficacy benefits to the pharmacology, medical, veterinary and cosmetic industries. Side effects could be reduced by localized delivery and programmed delivery rates. Needle stick injuries and needle disposable problems could be eliminated while the reduction in the level of skill required for application could significantly reduce total cost of many health programmes. These clear commercial benefits may only be achievable if the skin's natural barrier effect can be overcome.

OBJ is the first company to create a broad spectrum through-the-skin delivery system that is kind to the skin, completely reversible, yet can handle drugs range from the small difficult molecules up to the largest and most complex proteins and anti-bodies. OBJ manages an extensive IP portfolio and prosecutes patent applications throughout the world.

Independence of Results

OBJ contracts its drug and technology testing programs to independent and respected organisations, such as Western Australian Biomedical Research Institute, Western Australian Institute for Medical Research, Curtin University of Technology and Murdoch University. The high level of independence and international accreditation means that the results attributable to OBJ's proprietary technology can be published and presented at major medical and scientific conferences and forums.

For more information:

Jeffrey Edwards

Phone: +61 9 944 33011 Mobile: 041 791 2211 E-mail: jedwards@obj.com.au